vs
Side-by-side financial comparison of Autolus Therapeutics plc (AUTL) and Cheche Group Inc. (CCG). Click either name above to swap in a different company.
Cheche Group Inc. is the larger business by last-quarter revenue ($32.8M vs $21.2M, roughly 1.5× Autolus Therapeutics plc). Cheche Group Inc. runs the higher net margin — 0.5% vs -373.3%, a 373.8% gap on every dollar of revenue.
Autolus Therapeutics plc is a clinical-stage biopharmaceutical company specializing in the development of next-generation engineered chimeric antigen receptor T-cell (CAR-T) therapies for the treatment of hematological malignancies and solid tumors. It operates in the global oncology biotech market, advancing a pipeline of targeted immunotherapy candidates across multiple clinical development stages.
Cheche Group Inc. is a leading automotive digital service provider headquartered in China. It offers integrated solutions including auto insurance intermediary services, smart auto after-sales support, and connected vehicle technology products, serving individual car owners, auto dealerships, and insurance partners across domestic and select Southeast Asian markets.
AUTL vs CCG — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $21.2M | $32.8M |
| Net Profit | $-79.1M | $153.6K |
| Gross Margin | — | 5.7% |
| Operating Margin | -337.9% | — |
| Net Margin | -373.3% | 0.5% |
| Revenue YoY | — | — |
| Net Profit YoY | 3.6% | — |
| EPS (diluted) | $-0.30 | $0.00 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $32.8M | ||
| Q3 25 | $21.2M | — | ||
| Q2 25 | $20.9M | $26.0M | ||
| Q1 25 | $9.0M | — | ||
| Q4 24 | — | $18.6M | ||
| Q3 24 | $0 | — | ||
| Q2 24 | $0 | $36.1M | ||
| Q1 24 | $10.1M | — |
| Q1 26 | — | $153.6K | ||
| Q3 25 | $-79.1M | — | ||
| Q2 25 | $-47.9M | $-492.4K | ||
| Q1 25 | $-70.2M | — | ||
| Q4 24 | — | $-196.7K | ||
| Q3 24 | $-82.1M | — | ||
| Q2 24 | $-58.3M | $-7.6M | ||
| Q1 24 | $-52.7M | — |
| Q1 26 | — | 5.7% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 4.9% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 5.2% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 4.3% | ||
| Q1 24 | — | — |
| Q1 26 | — | — | ||
| Q3 25 | -337.9% | — | ||
| Q2 25 | -292.6% | -2.0% | ||
| Q1 25 | -726.3% | — | ||
| Q4 24 | — | -0.3% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -4.7% | ||
| Q1 24 | -384.1% | — |
| Q1 26 | — | 0.5% | ||
| Q3 25 | -373.3% | — | ||
| Q2 25 | -229.0% | -1.9% | ||
| Q1 25 | -781.1% | — | ||
| Q4 24 | — | -1.1% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -21.0% | ||
| Q1 24 | -522.1% | — |
| Q1 26 | — | $0.00 | ||
| Q3 25 | $-0.30 | — | ||
| Q2 25 | $-0.18 | $-0.01 | ||
| Q1 25 | $-0.26 | — | ||
| Q4 24 | — | $-0.00 | ||
| Q3 24 | $-0.31 | — | ||
| Q2 24 | $-0.22 | — | ||
| Q1 24 | $-0.24 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $86.1M | $20.0M |
| Total DebtLower is stronger | — | $193.3K |
| Stockholders' EquityBook value | $265.5M | — |
| Total Assets | $661.9M | $203.5M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $20.0M | ||
| Q3 25 | $86.1M | — | ||
| Q2 25 | $123.8M | $23.1M | ||
| Q1 25 | $95.8M | — | ||
| Q4 24 | — | $21.1M | ||
| Q3 24 | $657.1M | — | ||
| Q2 24 | $705.9M | $28.2M | ||
| Q1 24 | $758.5M | — |
| Q1 26 | — | $193.3K | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $690.0K | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q1 26 | — | — | ||
| Q3 25 | $265.5M | — | ||
| Q2 25 | $346.5M | $47.1M | ||
| Q1 25 | $371.1M | — | ||
| Q4 24 | — | $49.1M | ||
| Q3 24 | $477.0M | — | ||
| Q2 24 | $527.8M | $48.6M | ||
| Q1 24 | $582.0M | — |
| Q1 26 | — | $203.5M | ||
| Q3 25 | $661.9M | — | ||
| Q2 25 | $721.0M | $177.3M | ||
| Q1 25 | $746.3M | — | ||
| Q4 24 | — | $177.7M | ||
| Q3 24 | $827.5M | — | ||
| Q2 24 | $853.6M | $139.3M | ||
| Q1 24 | $901.4M | — |
| Q1 26 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.01× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-67.9M | — |
| Free Cash FlowOCF − Capex | $-72.3M | — |
| FCF MarginFCF / Revenue | -341.2% | — |
| Capex IntensityCapex / Revenue | 20.8% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-322.5M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q3 25 | $-67.9M | — | ||
| Q2 25 | $-72.8M | $-44.7M | ||
| Q1 25 | $-75.6M | — | ||
| Q4 24 | — | $-15.8M | ||
| Q3 24 | $-76.7M | — | ||
| Q2 24 | $-51.1M | $-1.0K | ||
| Q1 24 | $-40.5M | — |
| Q1 26 | — | — | ||
| Q3 25 | $-72.3M | — | ||
| Q2 25 | $-80.1M | — | ||
| Q1 25 | $-83.8M | — | ||
| Q4 24 | — | $-16.0M | ||
| Q3 24 | $-86.3M | — | ||
| Q2 24 | $-51.9M | $-1.1K | ||
| Q1 24 | $-41.0M | — |
| Q1 26 | — | — | ||
| Q3 25 | -341.2% | — | ||
| Q2 25 | -382.6% | — | ||
| Q1 25 | -933.1% | — | ||
| Q4 24 | — | -85.9% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -0.0% | ||
| Q1 24 | -406.8% | — |
| Q1 26 | — | — | ||
| Q3 25 | 20.8% | — | ||
| Q2 25 | 34.8% | — | ||
| Q1 25 | 91.8% | — | ||
| Q4 24 | — | 1.2% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 0.0% | ||
| Q1 24 | 5.3% | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
